| |
|
|
|
Xtalks, Online
2025-11-04
Digital biomarkers have advanced from pilots into assets that can change development decisions if they are built, validated and governed with purpose. This webinar convenes leaders from academia and biopharma involved in patient monitoring, machine learning/AI and digital strategies across Parkinson’s disease, Alzheimer’s disease and HIV-associated mild cognitive impairment. Their experience in cognition, speech and mobility, along with lessons from stalled efforts, offers a clear view of turning high-frequency signals into decision-grade evidence.
This webinar will move beyond feature lists to what matters for sponsors: Which digital measures are clinically meaningful and durable, not just statistically interesting? How does the context of use, trial design and evidence packages align so digital endpoints accelerate time-to-insight? Where do foundation models, multimodal fusion and privacy-preserving learning de-risk programs, and where are they overhyped?
The featured speakers will show how successful teams connect four planes of work: (1) crisp problem definition anchored to patient-relevant outcomes; (2) validation plans and pipelines that anticipate real-world variability, device churn and regulatory expectations; (3) transparent AI that links model behavior to pathophysiology and clinician intuition; and (4) governance that treats data rights, security and interoperability as enablers of reuse. They will also highlight the failure modes that quietly sink initiatives, including mis-specified labels, cohort bias and lab-to-life performance gaps, and what “good” looks like when measures are ready for pivotal decisions.
Register for this webinar to learn how digital biomarkers can evolve into decision-grade evidence that accelerates clinical development.
Keywords: AI, Basic Research, Biomarkers, Clinical Data, Clinical Research, Clinical Trials, CNS, Cognitive Impairment, CRO, Digital Biomarker, Digital Endpoints, Digital Health Technology, Drug Development, Neurological Disorder, Patient Outcomes, Therapeutic Areas
|
|
|
|
|
|
|
|
Organized by:
|
|
Xtalks |
|
|
Invited Speakers:
|
|
Josh Cosman, PhD, Scientific Director, Precision Medicine, AbbVie Inc.
Leah Rubin, Professor of Neurology, Psychiatry and Behavioral Sciences, Molecular and Comparative Pathobiology, and Epidemiology, Johns Hopkins University
Raha Dastgheyb, Assistant Professor of Neurology, Johns Hopkins School of Medicine
Bryan J. Hansen, PhD, Pharma Neuroscientist, Technologist, and Innovator
Tairmae Kangarloo, Former Associate Director Digital Strategy
David Anderson, Director, Science & Innovation, Clinical ink
|
|
|
|
|
|
|
|
Deadline for Abstracts:
|
|
2025-11-04
|
|
|
|
|
|
|
|
Registration:
|
|
Free Registration
|
|
|
E-mail:
|
|
tristan@xtalks.com
|
|
|
|
|
|
|
|
|